The reactions of 2H-1,2,3-diazaarsoles with phenyl azide

2-Phenyl-5-methyl- and 2,5-diphenyl-2H-1,2,3-diazaarsoles 1a,b react with phenyl azide to give several crystalline products: tricyclic derivatives 2a,b and 4,4′-bis(2H-1,2,3-diazaarsoles) 5a,b formed at room temperature, and a cycloadduct 6a obtained at + 4°C. Compound 6a undergoes a fast rearrangement in solutions of Et3N or pyridine to give a stable dicoordinate arsenic compound, the 2H-1,2,3-diazaarsole 7a. Heating solutions of 2a under reflux in an inert atmosphere leads to 5a and of 2b, in the presence of water, to 4b. The structures of 2a, 4b, and 7a were characterized by X-ray crystal structure determinations. © 1996 John Wiley & Sons, Inc

Use of pharmacoinvasive approach to the treatment of patients with ST segment elevation acute coronary syndrome: state of the problem

Role of pharmacoinvasive tactics in the treatment of patients with ST-segment elevation acute myocardial infarction is considered. The expert opinions reflected in the final version of the guideline are given, as well as the results of clinical trials in which the efficacy of thrombolytic therapy at early stage after acute myocardial infarction onset comparedwith primary percutaneous coronary intervention. The place of pharmacoinvasive tactics in real clinical practice is discussed

Терапія післяопераційних ран армованими пов’язками на основі пекти-ну та їх протимікробна дія

A reinforced pectin-based dressing with a reinforcing element containing the antimicrobial agent chlorhexidine bigluconate has been developed. In vitro studies have shown that the hydrogel pectin dressing containing 0.03 ÷ 1.5 % chlorhexidine bigluconate inhibits the growth of both gram-positive (S. aureus) and gram-negative (P. aeruginosa) bacteria. The dressing can be used in the complex treatment of postoperative wounds with infectious-inflammatory process. The efficacy of different doses of chlorhexidine bigluconate was characterized by growth inhibition and increase of microorganism-free areas on the culture medium around the site of dressing localization, and regardless of the type of bacteria. Bacterial growth inhibition radius size depends on the dose of chlorhexidine in the hydrogel pectin dressing. The inhibition of growth of S. aureus and P. aeruginosa is directly proportional to chlorhexidine bigluconate content. The increase of dressing saturation with chlorhexidine to 1.0 and 1.5 % recorded the maximum inhibition of the growth of microorganisms. A veterinary clinical trial has shown a good therapeutic effect in the wound healing, in particular in the complex treatment of postoperative and accidental wounds both in the presence of infectious-inflammatory process and in its absence. The reinforced pectin-based dressing with cotton (or polypropylene) reinforcement element containing chlorhexidine bigluconate reduces the cost of dressings and bandaging frequency during wound healing. It protects the wound surface from contamination, mechanical irritation, bacterial contamination and the development of secondary infection. The dressing promotes good water, air and heat exchange between the wound and the environment, adsorbs excess exudate, maintains a moist environment and does not cause hyperosmotic damage and drying of the wound. Surgical wound healing occurred under the initial tension for 7 days. Considering the method of its application, this dressing is suitable for use on different parts of the animal's body (neck, withers, chest and abdomen, lower back, buttocks, thighs, shoulders, etc.).Розроблено армовану пов’язку на основі пектину з елементом армування, що містить антимікробний засіб хлоргексидин біглюконат. Проведені дослідження in vitro показали, що гідрогелева пектинова пов’язка з вмістом 0,03 ÷ 1,5 % хлоргексидину біглюконату пригнічує ріст як грампозитивних (S. aureus), так і грамнегативних (P. aeruginosa) бактерій. Завдяки цьому пов’язка може бути використана і за комплексного лікування післяопераційних ран з інфекційно-запальним процесом. Ефективність дії різних доз хлоргексидину біглюконату характеризувалася пригніченням росту та збільшенням вільного від мікроорганізмів зон середовища культивування навколо місця локалізації пов’язки з діючою речовиною, незалежно від виду бактерій. Однак величина діаметру зони пригнічення росту бактерій залежить від дози хлоргексидину в гідрогелевій пектиновій пов’язці. За пропорційного підвищення вмісту хлоргексидину біглюконату інгібування росту S. aureus і P. aeruginosa посилюється. Так, коли збільшували насичення пов’язки хлоргексидином до 1,0 і 1,5 %, реєстрували максимальне інгібування росту мікроорганізмів. Клінічне дослідження показало добрий лікувальний ефект у ветеринарній практиці за терапії ран, зокрема за комплексного лікування післяопераційних і випадкових ран як за наявності інфекційно-запального процесу, так і за його відсутності. Застосування армованої пов’язки на основі пектину з бавовняним (чи поліпропіленовим) елементом армування з вмістом хлоргексидину біглюконату скорочує витрати перев'язувального матеріалу і частоту перев’язок впродовж часу загоєння ран. Вона забезпечує захист ранової поверхні від забруднення, механічного подразнення, бактеріальної контамінації та розвитку вторинної інфекції. Пов’язка сприяє доброму водо-, повітро- та теплообміну між раною та зовнішнім середовищем, адсорбує надлишок ексудату, підтримує вологе середовище і не викликає гіперосмотичного ушкодження й висихання рани. Загоювання післяопераційної рани відбулося за первинним натягом впродовж 7 діб. Зважаючи на спосіб накладання, дана пов’язка може бути придатна для застосування у різних ділянках тіла тварини (шиї, холки, грудної й черевної стінок, попереку, крижів, стегна, плеча тощо)

The reactions of 2H-1,2,3-diazaarsoles with phenyl azide

2-Phenyl-5-methyl- and 2,5-diphenyl-2H-1,2,3-diazaarsoles 1a,b react with phenyl azide to give several crystalline products: tricyclic derivatives 2a,b and 4,4′-bis(2H-1,2,3-diazaarsoles) 5a,b formed at room temperature, and a cycloadduct 6a obtained at + 4°C. Compound 6a undergoes a fast rearrangement in solutions of Et3N or pyridine to give a stable dicoordinate arsenic compound, the 2H-1,2,3-diazaarsole 7a. Heating solutions of 2a under reflux in an inert atmosphere leads to 5a and of 2b, in the presence of water, to 4b. The structures of 2a, 4b, and 7a were characterized by X-ray crystal structure determinations. © 1996 John Wiley & Sons, Inc

The reactions of 2H-1,2,3-diazaarsoles with phenyl azide

2-Phenyl-5-methyl- and 2,5-diphenyl-2H-1,2,3-diazaarsoles 1a,b react with phenyl azide to give several crystalline products: tricyclic derivatives 2a,b and 4,4′-bis(2H-1,2,3-diazaarsoles) 5a,b formed at room temperature, and a cycloadduct 6a obtained at + 4°C. Compound 6a undergoes a fast rearrangement in solutions of Et3N or pyridine to give a stable dicoordinate arsenic compound, the 2H-1,2,3-diazaarsole 7a. Heating solutions of 2a under reflux in an inert atmosphere leads to 5a and of 2b, in the presence of water, to 4b. The structures of 2a, 4b, and 7a were characterized by X-ray crystal structure determinations. © 1996 John Wiley & Sons, Inc

The reactions of 2H-1,2,3-diazaarsoles with phenyl azide

2-Phenyl-5-methyl- and 2,5-diphenyl-2H-1,2,3-diazaarsoles 1a,b react with phenyl azide to give several crystalline products: tricyclic derivatives 2a,b and 4,4′-bis(2H-1,2,3-diazaarsoles) 5a,b formed at room temperature, and a cycloadduct 6a obtained at + 4°C. Compound 6a undergoes a fast rearrangement in solutions of Et3N or pyridine to give a stable dicoordinate arsenic compound, the 2H-1,2,3-diazaarsole 7a. Heating solutions of 2a under reflux in an inert atmosphere leads to 5a and of 2b, in the presence of water, to 4b. The structures of 2a, 4b, and 7a were characterized by X-ray crystal structure determinations. © 1996 John Wiley & Sons, Inc

THE PROBLEM OF THE OPTIMAL PHARMACOTHERAPY CHOICE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE

The problem of the "optimal pharmacotherapy" choice in patients with stable coronary artery disease is discussed. Expert’s opinions are presented concerning first-line antiischemic drugs and about current approaches to the choosing additional (adjuvant) antiischemic drugs. The practical application of optimal pharmacotherapy in patients with stable angina pectoris is also discussed.</p

INNOVATIVE TECHNOLOGIES IN CARDIOLOGY: FROM SURPRISE TO HABIT OR FORGETFULNESS

Change of the status of innovative technologies depending on the received evidences is considered. Examples reflecting the initiation of interest in the new technology of treatment, the transition from innovation to standard therapies, as well as the weakening of interest in the previously introduced technology due to disappointing results of clinical trials on evaluation of its effectiveness are presented.</p

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE

Alternative approaches to the use of two component antiplatelet therapy in patients with acute coronary syndrome are discussed. Reasons to the development and implementation of new, more powerful antiplatelet agents are considered. Besides the evidence base for the practical application of new antiplatelet agents is discussed, especially this for ticagrelor which is the first-line drug in acute coronary syndrome according to European clinical guidelines. Subjective limitations of ticagrelor use in clinical practice are discussed, as well as a basis for overcoming these limitations.</p

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE

Alternative approaches to the use of two component antiplatelet therapy in patients with acute coronary syndrome are discussed. Reasons to the development and implementation of new, more powerful antiplatelet agents are considered. Besides the evidence base for the practical application of new antiplatelet agents is discussed, especially this for ticagrelor which is the first-line drug in acute coronary syndrome according to European clinical guidelines. Subjective limitations of ticagrelor use in clinical practice are discussed, as well as a basis for overcoming these limitations